.ANALYSIS HIGHLIGHT.16 Oct 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to regular treatment for muscle-invasive bladder cancer enhanced event-free as well as overall survival, denoting a brand-new procedure choice for this ailment.